New dietary ingredient notifications
This article was originally published in The Tan Sheet
Executive SummaryFDA should issue a guidance to explain when new dietary ingredient notifications are necessary, as well as the type of information they should include, NNFA says in May 9 letter to the agency. Guidance should establish "whether, and under what conditions, a dietary ingredient that is a component of food (i.e. lycopene in tomatoes) would be exempt" from notification, as well as the quantity, quality of information required to satisfy the "history of use or other evidence of safety" standard. NNFA's comments respond to March 19 FDA notice requesting public feedback on premarket notification process for new dietary ingredients...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.